Dr. Hwang on the Evolution of Treatment in Metastatic CSPC

Video

Clara Hwang, MD, discusses the evolution of treatment for men with metastatic castration-sensitive prostate cancer.

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the evolution of treatment for men with metastatic castration-sensitive prostate cancer (mCSPC).

Historically, the standard of care for men with metastatic prostate cancer was androgen deprivation therapy, says Hwang. Subsequently, docetaxel showed an overall survival (OS) benefit versus standard-of-care therapy in the phase III CHAARTED and STAMPEDE trials.

Additionally, abiraterone acetate (Zytiga) demonstrated an improvement in OS versus standard-of-care therapy in the phase III LATITUDE trial, leading to its approval in 2018 in men with newly diagnosed mCSPC.

In 2019, enzalutamide (Xtandi) and apalutamide (Erleada) were approved for the treatment of patients with newly diagnosed mCSPC based on findings from the phase III ARCHES and TITAN trials, respectively.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute